Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer

Human Pathology

Volumn 43, Issue 10, 2012, Pages 1638-1644

  Hussein, Yaser R ^a   Sood, Anil K ^b   Bandyopadhyay, Sudeshna ^a   Albashiti, Bassam ^a   Semaan, Assaad ^c   Nahleh, Zeina ^d   Roh, Juwon ^b   Han, Hee Dong ^b   Lopez Berestein, Gabriel ^b   Ali Fehmi, Rouba ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d USA   (United States)

Author keywords

Breast cancer; EZH2; Triple negative

Indexed keywords

CHITOSAN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; NANOPARTICLE; PROGESTERONE RECEPTOR; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE SILENCING; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866516020     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.12.004     Document Type: Article

References (27)

1. J.A. Simon, and J.W. Tamkun Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes Curr Opin Genet Dev 12 2002 210 218 (Pubitemid 34219494)
2. C.G. Kleer, Q. Cao, and S. Varambally EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci U S A 100 2003 11606 11611 (Pubitemid 37205983)
3. I.M. Bachmann, O.J. Halvorsen, and K. Collett EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast J Clin Oncol 24 2006 268 273 (Pubitemid 46622055)
4. S. Cleator, W. Heller, and R.C. Coombes Triple-negative breast cancer: therapeutic options Lancet Oncol 8 2007 235 244 (Pubitemid 46291713)
5. R. Rouzier, C.M. Perou, and W.F. Symmans Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 2005 5678 5685 (Pubitemid 41170290)
6. H.J. Bloom, and W.W. Richardson Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years Br J Cancer 11 1957 359 377
7. A. Spitale, P. Mazzola, D. Soldini, L. Mazzucchelli, and A. Bordoni Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland Ann Oncol 20 2009 628 635
8. P.L. Fitzgibbons, D.A. Murphy, M.E. Hammond, D.C. Allred, and P.N. Valenstein Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays Arch Pathol Lab Med 134 2010 930 935
9. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145 (Pubitemid 350003059)
10. S.E. Singletary, C. Allred, and P. Ashley Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual Surg Clin North Am 83 2003 803 819 (Pubitemid 36841911)
11. R.L. Camp, L.A. Charette, and D.L. Rimm Validation of tissue microarray technology in breast carcinoma Lab Invest 80 2000 1943 1949 (Pubitemid 32012762)
12. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874 (Pubitemid 32878711)
13. A. Alkushi, P. Lim, A. Coldman, D. Huntsman, D. Miller, and C.B. Gilks Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level Int J Gynecol Pathol 23 2004 129 137 (Pubitemid 38391772)
14. C.N. Landen Jr., A. Chavez-Reyes, and C. Bucana Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery Cancer Res 65 2005 6910 6918 (Pubitemid 41060730)
15. P.H. Thaker, L.Y. Han, and A.A. Kamat Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med 12 2006 939 944 (Pubitemid 44175146)
16. C. Lu, H.D. Han, and L.S. Mangala Regulation of tumor angiogenesis by EZH2 Cancer Cell 18 2010 185 197
17. F.M. Raaphorst, C.J. Meijer, and E. Fieret Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene Neoplasia 5 2003 481 488 (Pubitemid 38045085)
18. K. Collett, G.E. Eide, and J. Arnes Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer Clin Cancer Res 12 2006 1168 1174 (Pubitemid 43342505)
19. C.G. Kleer Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions Arch Pathol Lab Med 133 2009 1822 1825
20. X. Tang, M. Milyavsky, I. Shats, N. Erez, N. Goldfinger, and V. Rotter Activated p53 suppresses the histone methyltransferase EZH2 gene Oncogene 23 2004 5759 5769 (Pubitemid 39093021)
21. A.P. Bracken, D. Pasini, M. Capra, E. Prosperini, E. Colli, and K. Helin EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J 22 2003 5323 5335 (Pubitemid 37279943)
22. S. Varambally, S.M. Dhanasekaran, and M. Zhou The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
23. M.E. Gonzalez, X. Li, and K. Toy Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1 Oncogene 28 2009 843 853
24. B. Corkery, J. Crown, M. Clynes, and N. O'Donovan Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann Oncol 20 2009 862 867
25. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
26. C. Bengala Recent advances in managing triple-negative breast cancers F1000 Med Rep 1 2009 75 10.3410/M1-75
27. A. Kirmizis, S.M. Bartley, and P.J. Farnham Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy Mol Cancer Ther 2 2003 113 121